Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 24, 2026Investment Snapshot
- Trading 7,589% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 2.0% — below-average profitability
- Revenue growing at 65% annually
Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $40.7 billion . Key value metrics: P/E ratio 2,580.9, P/B ratio 51.54, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Alnylam Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) is currently trading 7,589% above its Graham Number of $3.99, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 2,580.9x.
On financial health, ALNY shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 2.0% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.15.
StockPik's composite Value Score for ALNY is 34/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ALNY reports a high gross margin of 84.2% (sector average: 33.5%) and a modest operating margin of 9.4%.
ALNY shows revenue growing at 65% year-over-year, with earnings growing at 213%.